Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Steris (STE)

STERIS adds Pierre Boulud to board; director Richard Breeden will not seek reelection

Neutral Impact 2 of 5 leadership Written later

STERIS plc appointed Pierre Boulud, CEO of bioMérieux, to its Board of Directors effective May 5, 2026, and increased the Board from nine to ten members. Director Richard C. Breeden, who has served 18 years, will not stand for reelection at the 2026 Annual General Meeting, and the company said his decision was not due to any disagreement with the company. The filing reports no financial results or guidance changes, so the event mainly affects board composition.

Key points

  • Pierre Boulud was appointed director effective May 5, 2026; the Board increased from nine to ten members.
  • Richard C. Breeden notified the company on May 1, 2026 that he will not stand for reelection at the 2026 Annual General Meeting, after 18 years as a director.
  • Boulud has been CEO of bioMérieux since June 2023 and will receive a prorated fee of $76,989 for the rest of the 2025-26 term, paid in career restricted stock units.

The filing

CompanySteris (STE)
Form8-K, current report
Filed with the SECMay 7, 2026, 4:35 PM ET
Accession number0001193125-26-212159

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.